Chinook Therapeutics Stock Cash Per Share
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Chinook Therapeutics fundamentals help investors to digest information that contributes to Chinook Therapeutics' financial success or failures. It also enables traders to predict the movement of Chinook Stock. The fundamental analysis module provides a way to measure Chinook Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Chinook Therapeutics stock.
Chinook |
Chinook Therapeutics Company Cash Per Share Analysis
Chinook Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Chinook Therapeutics Cash Per Share | 5.76 X |
Most of Chinook Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chinook Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Chinook Therapeutics has a Cash Per Share of 5.76 times. This is 32.41% higher than that of the Biotechnology sector and 33.03% higher than that of the Health Care industry. The cash per share for all United States stocks is 14.97% lower than that of the firm.
Chinook Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chinook Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics of similar companies.Chinook Therapeutics is currently under evaluation in cash per share category among its peers.
Chinook Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (39.98) % | |||
| Current Valuation | 2.64 B | |||
| Shares Outstanding | 67.05 M | |||
| Shares Owned By Insiders | 2.19 % | |||
| Shares Owned By Institutions | 96.71 % | |||
| Number Of Shares Shorted | 2.88 M | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 27.90 X | |||
| Revenue | 6.13 M | |||
| Gross Profit | (135.08 M) | |||
| EBITDA | (164.2 M) | |||
| Net Income | (187.87 M) | |||
| Cash And Equivalents | 362.61 M | |||
| Cash Per Share | 5.76 X | |||
| Total Debt | 39.44 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 12.60 X | |||
| Book Value Per Share | 5.32 X | |||
| Cash Flow From Operations | (117.48 M) | |||
| Short Ratio | 3.43 X | |||
| Earnings Per Share | (3.24) X | |||
| Price To Earnings To Growth | (0.99) X | |||
| Target Price | 40.3 | |||
| Number Of Employees | 214 | |||
| Beta | 0.67 | |||
| Market Capitalization | 2.71 B | |||
| Total Asset | 574.08 M | |||
| Retained Earnings | (419.63 M) | |||
| Working Capital | 334.76 M | |||
| Z Score | 39.94 | |||
| Net Asset | 574.08 M |
About Chinook Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chinook Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |